Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells
- PMID: 36841178
- PMCID: PMC10198888
- DOI: 10.1016/j.modpat.2023.100122
Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells
Abstract
Olfactory neuroblastoma (ONB, esthesioneuroblastoma) is a sinonasal cancer with an underdeveloped diagnostic toolkit, and is the subject of many incidents of tumor misclassification throughout the literature. Despite its name, connections between the cancer and normal cells of the olfactory epithelium have not been systematically explored and markers of olfactory epithelial cell types are not deployed in clinical practice. Here, we utilize an integrated human-mouse single-cell atlas of the nasal mucosa, including the olfactory epithelium, to identify transcriptomic programs that link ONB to a specific population of stem/progenitor cells known as olfactory epithelial globose basal cells (GBCs). Expression of a GBC transcription factor NEUROD1 distinguishes both low- and high-grade ONB from sinonasal undifferentiated carcinoma, a potential histologic mimic with a distinctly unfavorable prognosis. Furthermore, we identify a reproducible subpopulation of highly proliferative ONB cells expressing the GBC stemness marker EZH2, suggesting that EZH2 inhibition may play a role in the targeted treatment of ONB. Finally, we study the cellular states comprising ONB parenchyma using single-cell transcriptomics and identify evidence of a conserved GBC transcriptional regulatory circuit that governs divergent neuronal-versus-sustentacular differentiation. These results link ONB to a specific cell type for the first time and identify conserved developmental pathways within ONB that inform diagnostic, prognostic, and mechanistic investigation.
Keywords: esthesioneuroblastoma; head and neck cancer; olfactory epithelium; olfactory neuroblastoma; transcriptomics.
Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
CONFLICT OF INTEREST STATEMENT
JES and EHH are a co-founders of Rejuvenos Therapeutics, Ltd. and JES is a co-founder of Rhino Therapeutics. Authors declare that they have no competing interests.
Figures





References
-
- Berger L, Luc G. L’esthesioneuroepitheliome olfactif. Bull Assoc Fr Etude Cancer. 1924;13:410–21.
-
- Berger L, Coutard H. L’esthesioneurocytome olfactif. Bull Assoc Fr Etude Cancer. 1926;15:404–14.
-
- Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001. Nov 1;2(11):683–90. - PubMed
-
- Faragalla H, Weinreb I. Olfactory Neuroblastoma: A Review and Update. Adv Anat Pathol. 2009. Sep;16(5):322. - PubMed
-
- Elkon D, Hightower SI, Lim ML, et al. Esthesioneuroblastoma. Cancer. 1979;44(3):1087–94. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases